UZH-Logo

Maintenance Infos

Browse by Creators - Zurich Open Repository and Archive

Navigate back| Up a level
Export as
Number of items: 64.

Cusini, A; Vernazza, P L; Yerly, S; Decosterd, L A; Ledergerber, B; Fux, C A; Rohrbach, J; Widmer, N; Hirschel, B; Gaudenz, R; Cavassini, M; Klimkait, Th; Zenger, F; Gutmann, C; Opravil, M; Günthard, H F (2013). Higher CNS Penetration-Effectiveness of long-term combination antiretroviral therapy is associated with better HIV-1 viral suppression in cerebrospinal fluid. Journal of Acquired Immune Deficiency Syndromes, 62(1):28-35.

Stern, M; Czaja, K; Rauch, A; Rickenbach, M; Günthard, H F; Battegay, M; Fellay, J; Hirschel, B; Hess, C (2012). HLA-Bw4 identifies a population of HIV-infected patients with an increased capacity to control viral replication after structured treatment interruption. HIV Medicine, 13(10):589-595.

L'huillier, A G; Ferry, T; Courvoisier, D S; Aebi, C; Cheseaux, J J; Kind, C; Rudin, C; Nadal, D; Hirschel, B; Sottas, C; Siegrist, C A; Posfay-Barbe, K M (2012). Impaired antibody memory to varicella zoster virus in HIV-infected children: low antibody levels and avidity(*). HIV Medicine, 13(1):54-61.

von Wyl, V; Yerly, S; Böni, J; Shah, C; Cellerai, C; Klimkait, T; Battegay, M; Bernasconi, E; Cavassini, M; Furrer, H; Hirschel, B; Vernazza, P L; Ledergerber, B; Günthard, H F (2012). Incidence of HIV-1 drug resistance among antiretroviral treatment-naive individuals starting modern therapy combinations. Clinical Infectious Diseases, 54(1):131-140.

Wandeler, G; Keiser, O; Hirschel, B; Günthard, H F; Bernasconi, E; Battegay, M; Clerc, O; Vernazza, P L; Furrer, H (2011). A comparison of initial antiretroviral therapy in the Swiss HIV Cohort Study and the recommendations of the International AIDS Society-USA. PLoS ONE, 6(12):e27903.

Kouyos, R D; von Wyl, V; Yerly, S; Böni, J; Rieder, P; Joos, B; Taffé, P; Shah, C; Bürgisser, P; Klimkait, T; Weber, R; Hirschel, B; Cavassini, M; Rauch, A; Battegay, M; Vernazza, P L; Bernasconi, E; Ledergerber, B; Bonhoeffer, S; Günthard, H F (2011). Ambiguous nucleotide calls from population-based sequencing of HIV-1 are a marker for viral diversity and the age of infection. Clinical Infectious Diseases, 52(4):532-539.

Lubomirov, R; Colombo, S; di Iulio, J; Ledergerber, B; Martinez, R; Cavassini, M; Hirschel, B; Bernasconi, E; Elzi, L; Vernazza, P; Furrer, H; Günthard, H F; Telenti, A (2011). Association of pharmacogenetic markers with premature discontinuation of first-line anti-HIV therapy: an observational cohort study. Journal of Infectious Diseases, 203(2):246-257.

El Amari, E B; Combescure, C; Yerly, S; Calmy, A; Kaiser, L; Hasse, B; Furrer, H; Cavassini, M; Vernazza, P; Hirsch, H H; Bernasconi, E; Hirschel, B (2011). Clinical relevance of cytomegalovirus viraemia(*,†). HIV Medicine, 12(7):394-402.

Rotger, M; Dalmau, J; Rauch, A; McLaren, P; Bosinger, S E; Martinez, R; Sandler, N G; Roque, A; Liebner, J; Battegay, M; Bernasconi, E; Descombes, P; Erkizia, I; Fellay, J; Hirschel, B; Miró, J M; Palou, E; Hoffmann, M; Massanella, M; Blanco, J; Woods, M; Günthard, H F; de Bakker, P; Douek, D C; Silvestri, G; Martinez-Picado, J; Telenti, A (2011). Comparative transcriptomics of extreme phenotypes of human HIV-1 infection and SIV infection in sooty mangabey and rhesus macaque. Journal of Clinical Investigation, 121(6):2391-2400.

von Wyl, V; Gianella, S; Fischer, M; Niederoest, B; Kuster, H; Battegay, M; Bernasconi, E; Cavassini, M; Rauch, A; Hirschel, B; Vernazza, P; Weber, R; Joos, B; Günthard, H F (2011). Early antiretroviral therapy during primary HIV-1 infection results in a transient reduction of the viral setpoint upon treatment interruption. PLoS ONE, 6(11):e27463.

Gianella, S; von Wyl, V; Fischer, M; Niederoest, B; Battegay, M; Bernasconi, E; Cavassini, M; Rauch, A; Hirschel, B; Vernazza, P; Weber, R; Joos, B; Günthard, H F (2011). Effect of early antiretroviral therapy during primary HIV-1 infection on cell-associated HIV-1 DNA and plasma HIV-1 RNA. Antiviral Therapy, 16(4):535-545.

Young, J; Scherrer, A; Günthard, H; Opravil, M; Yerly, S; Böni, J; Rickenbach, M; Fux, C; Cavassini, M; Bernasconi, E; Vernazza, P; Hirschel, B; Battegay, M; Bucher, H (2011). Efficacy, tolerability and risk factors for virological failure of darunavir-based therapy for treatment-experienced HIV-infected patients: the Swiss HIV Cohort Study. HIV Medicine, 12(5):299-307.

di Iulio, J; Ciuffi, A; Fitzmaurice, K; Kelleher, D; Rotger, M; Fellay, J; Martinez, R; Pulit, S; Furrer, H; Günthard, H F; Battegay, M; Bernasconi, E; Schmid, P; Hirschel, B; Barnes, E; Klenerman, P; Telenti, A; Rauch, A (2011). Estimating the net contribution of interleukin-28B variation to spontaneous hepatitis C virus clearance. Hepatology, 53(5):1446-1454.

Elzi, L; Steffen, I; Furrer, H; Fehr, J; Cavassini, M; Hirschel, B; Hoffmann, M; Bernasconi, E; Bassetti, S; Battegay, M (2011). Improved sensitivity of an interferon-gamma release assay (T-SPOT.TB™) in combination with tuberculin skin test for the diagnosis of latent tuberculosis in the presence of HIV co-infection. BMC Infectious Diseases, 11:319.

Scherrer, A U; Ledergerber, B; von Wyl, V; Böni, J; Yerly, S; Klimkait, T; Bürgisser, P; Rauch, A; Hirschel, B; Cavassini, M; Elzi, L; Vernazza, P L; Bernasconi, E; Held, L; Günthard, H F (2011). Improved virological outcome in white patients infected with HIV-1 non-B subtypes compared to subtype B. Clinical Infectious Diseases, 53(11):1143-1152.

Kaufmann, G R; Elzi, L; Weber, R; Furrer, H; Giulieri, S; Vernazza, P; Bernasconi, E; Hirschel, B; Battegay, M (2011). Interruptions of cART limits CD4 T-cell recovery and increases the risk for opportunistic complications and death. AIDS, 25(4):441-451.

Magenta, L; Dell-Kuster, S; Richter, W O; Young, J; Hasse, B; Flepp, M; Hirschel, B; Vernazza, P; Evison, J; Cavassini, M; Decosterd, L A; Bucher, H C; Bernasconi, E (2011). Lipid and lipoprotein profile in HIV-infected patients treated with Lopinavir/Ritonavir as a component of the first combination antiretroviral therapy. AIDS Research and Human Retroviruses, 27(5):525-533.

Hasse, B; Ledergerber, B; Furrer, H; Battegay, M; Hirschel, B; Cavassini, M; Bertisch, B; Bernasconi, E; Weber, R (2011). Morbidity and aging in HIV-infected persons: the Swiss HIV cohort study. Clinical Infectious Diseases, 53(11):1130-1139.

Ortiz, M; Poloni, E S; Furrer, H; Kovari, H; Martinez, R; Arnedo, M; Elzi, L; Bernasconi, E; Vernazza, P; Hirschel, B; Cavassini, M; Ledergerber, B; Günthard, H F; Telenti, A; Tarr, P E (2011). No longitudinal mitochondrial DNA sequence changes in HIV-infected individuals with and without lipoatrophy. Journal of Infectious Diseases, 203(5):620-624.

Fehr, J; Glass, T R; Louvel, S; Hamy, F; Hirsch, H H; von Wyl, V; Böni, J; Yerly, S; Bürgisser, P; Cavassini, M; Fux, C A; Hirschel, B; Vernazza, P; Martinetti, G; Bernasconi, E; Günthard, H F; Battegay, M; Bucher, H C; Klimkait, T (2011). Replicative phenotyping adds value to genotypic resistance testing in heavily pre-treated HIV-infected individuals--the Swiss HIV Cohort Study. Journal of Translational Medicine, 9:14.

Haas, A; Zimmermann, K; Graw, F; Slack, E; Rusert, P; Ledergerber, B; Bossart, W; Weber, R; Thurnheer, M C; Battegay, M; Hirschel, B; Vernazza, P; Patuto, N; Macpherson, A J; Günthard, H F; Oxenius, A (2011). Systemic antibody responses to gut commensal bacteria during chronic HIV-1 infection. Gut, 60(11):1506-1519.

von Wyl, V; Kouyos, R D; Yerly, S; Böni, J; Shah, C; Bürgisser, P; Klimkait, T; Weber, R; Hirschel, B; Cavassini, M; Staehelin, C; Battegay, M; Vernazza, P L; Bernasconi, E; Ledergerber, B; Bonhoeffer, S; Günthard, H F (2011). The role of migration and domestic transmission in the spread of HIV-1 non-B subtypes in Switzerland. Journal of Infectious Diseases, 204(7):1095-1103.

Ledergerber, B; Cavassini, M; Battegay, M; Bernasconi, E; Vernazza, P; Hirschel, B; Furrer, H; Rickenbach, M; Weber, R (2011). Trends over time of virological and immunological characteristics in the Swiss HIV Cohort Study. HIV Medicine, 12(5):279-288.

Scherrer, A U; von Wyl, V; Böni, J; Yerly, S; Klimkait, T; Bürgisser, P; Garzoni, C; Hirschel, B; Cavassini, M; Battegay, M; Vernazza, P L; Bernasconi, E; Ledergerber, B; Günthard, H F (2011). Viral suppression rates in salvage treatment with raltegravir improved with the administration of genotypic partially active or inactive nucleoside/tide reverse transcriptase inhibitors. JAIDS Journal of Acquired Immune Deficiency Syndromes, 57(1):24-31.

Glass, T R; Battegay, M; Cavassini, M; De Geest, S; Furrer, H; Vernazza, P L; Hirschel, B; Bernasconi, E; Rickenbach, M; Günthard, H F; Bucher, H C (2010). Longitudinal analysis of patterns and predictors of changes in self-reported adherence to antiretroviral therapy: Swiss HIV Cohort Study. JAIDS Journal of Acquired Immune Deficiency Syndromes, 54(2):197-203.

Scherrer, A U; von Wyl, V; Fux, C A; Opravil, M; Bucher, H C; Fayet, A; Decosterd, L A; Hirschel, B; Khanlari, B; Yerly, S; Klimkait, T; Furrer, H; Ledergerber, B; Günthard, H F (2010). Implementation of Raltegravir in routine clinical practice: Selection criteria for choosing this drug, virologic response rates, and characteristics of failures. JAIDS Journal of Acquired Immune Deficiency Syndromes, 53(4):464-471.

Rohrbach, J; Robinson, N; Harcourt, G; Hammond, E; Gaudieri, S; Gorgievski, M; Telenti, A; Keiser, O; Günthard, H F; Hirschel, B; Hoffmann, M; Bernasconi, E; Battegay, M; Furrer, H; Klenerman, P; Rauch, A (2010). Cellular immune responses to HCV core increase and HCV RNA levels decrease during successful antiretroviral therapy. Gut, 59(9):1252-1258.

Barnes, E; Flanagan, P; Brown, A; Robinson, N; Brown, H; McClure, M; Oxenius, A; Collier, J; Weber, J; Günthard, H F; Hirschel, B; Fidler, S; Phillips, R; Frater, J (2010). Failure to detect xenotropic murine leukemia virus-related virus in blood of individuals at high risk of blood-borne viral infections. Journal of Infectious Diseases, 202(10):1482-1485.

Hasse, B; Ledergerber, B; Hirschel, B; Vernazza, P; Glass, T R; Jeannin, A; Evison, J M; Elzi, L; Cavassini, M; Bernasconi, E; Nicca, D; Weber, R (2010). Frequency and determinants of unprotected sex among HIV-infected persons: the Swiss HIV cohort study. Clinical Infectious Diseases, 51(11):1314-1322.

Rauch, A; Kutalik, Z; Descombes, P; Cai, T; Di Iulio, J; Mueller, T; Bochud, M; Battegay, M; Bernasconi, E; Borovicka, J; Colombo, S; Cerny, A; Dufour, J F; Furrer, H; Günthard, H F; Heim, M; Hirschel, B; Malinverni, R; Moradpour, D; Müllhaupt, B; Witteck, A; Beckmann, J S; Berg, T; Bergmann, S; Negro, F; Telenti, A; Bochud, P Y (2010). Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study. Gastroenterology, 138(4):1338-1338-1345.e7 .

Rotger, M; Gsponer, T; Martinez, R; Taffé, P; Elzi, L; Vernazza, P; Cavassini, M; Bernasconi, E; Hirschel, B; Furrer, H; Weber, R; Ledergerber, B; Egger, M; Telenti, A; Tarr, P E; Swiss HIV Cohort Study (2010). Impact of single nucleotide polymorphisms and of clinical risk factors on new‐onset diabetes mellitus in HIV‐infected individuals. Clinical Infectious Diseases, 51(9):1090-1098.

Kovari, H; Ledergerber, B; Battegay, M; Rauch, A; Hirschel, B; Foguena, A K; Vernazza, P; Bernasconi, E; Mueller, N J; Weber, R (2010). Incidence and risk factors for chronic elevation of alanine aminotransferase levels in HIV-infected persons without hepatitis b or c virus co-infection. Clinical Infectious Diseases, 50(4):502-511.

Ferry, T; Hirschel, B; Dang, T; Meylan, P; Delhumeau, C; Rauch, A; Weber, R; Elzi, L; Bernasconi, E; Schmid, P; Calmy, A (2010). Infrequent replication of parvovirus B19 and erythrovirus genotypes 2 and 3 among HIV-infected patients with chronic anemia. Clinical Infectious Diseases, 50(1):115-118.

Kouyos, R D; von Wyl, V; Yerly, S; Böni, J; Taffé, P; Shah, C; Bürgisser, P; Klimkait, T; Weber, R; Hirschel, B; Cavassini, M; Furrer, H; Battegay, M; Vernazza, P L; Bernasconi, E; Rickenbach, M; Ledergerber, B; Bonhoeffer, S; Günthard, H F (2010). Molecular epidemiology reveals long-term changes in HIV type 1 subtype B transmission in Switzerland. Journal of Infectious Diseases, 201(10):1488-1497.

Alizon, S; von Wyl, V; Stadler, T; Kouyos, R D; Yerly, S; Hirschel, B; Böni, J; Shah, C; Klimkait, T; Furrer, H; Rauch, A; Vernazza, P L; Bernasconi, E; Battegay, M; Bürgisser, P; Telenti, A; Günthard, H F; Bonhoeffer, S; Swiss HIV Cohort Study (2010). Phylogenetic approach reveals that virus genotype largely determines HIV set-point viral load. PLoS Pathogens, 6(9):e1001123.

Gutmann, C; Cusini, A; Günthard, H F; Fux, C; Hirschel, B; Decosterd, L A; Cavassini, M; Yerly, S; Vernazza, P L (2010). Randomized controlled study demonstrating failure of LPV/r monotherapy in HIV: the role of compartment and CD4-nadir. AIDS, 24(15):2347-2354.

Elzi, L; Marzolini, C; Furrer, H; Ledergerber, B; Cavassini, M; Hirschel, B; Vernazza, P; Bernasconi, E; Weber, R; Battegay, M (2010). Treatment modification in human immunodeficiency virus-infected individuals starting combination antiretroviral therapy between 2005 and 2008. Archives of Internal Medicine, 170(1):57-65.

Rotger, M; Bayard, C; Taffé, P; Martinez, R; Cavassini, M; Bernasconi, E; Battegay, M; Hirschel, B; Furrer, H; Witteck, A; Weber, R; Ledergerber, B; Telenti, A; Tarr, P E (2009). Contribution of genome-wide significant single-nucleotide polymorphisms and antiretroviral therapy to dyslipidemia in HIV-infected individuals: a longitudinal study. Circulation: Cardiovascular Genetics, 2(6):621-628.

Elzi, L; Kaufmann, G; Weber, R; Fux, C A; Cavassini, M; Hirschel, B; Vernazza, P; Bernasconi, E; Battegay, M (2009). Discontinuation of enfuvirtide in heavily pretreated HIV-infected individuals. HIV Clinical Trials, 10(4):207-214.

Rauch, A; James, I; Pfafferott, K; Nolan, D; Klenerman, P; Cheng, W; Mollison, L; McCaughan, G; Shackel, N; Jeffrey, G P; Baker, R; Freitas, E; Humphreys, I; Furrer, F; Günthard, H F; Hirschel, B; Mallal, S; John, M; Lucas, M; Barnes, E; Gaudieri, S (2009). Divergent adaptation of hepatitis C virus genotypes 1 and 3 to human leukocyte antigen-restricted immune pressure. Hepatology, 50(4):1017-1029.

Combescure, C; Vallier, N; Ledergerber, B; Cavassini, M; Furrer, H; Rauch, A; Battegay, M; Bernasconi, E; Vernazza, P; Hirschel, B (2009). How reliable is an undetectable viral load? HIV Medicine, 10(8):470-476.

Ballif, M; Ledergerber, B; Battegay, M; Cavassini, M; Bernasconi, E; Schmid, P; Hirschel, B; Furrer, H; Rickenbach, M; Opravil, M; Weber, R (2009). Impact of previous virological treatment failures and adherence on the outcome of antiretroviral therapy in 2007. PLoS ONE, 4(12):e8275.

von Wyl, V; Yerli, S; Böni, J; Bürgisser, P; Klimkait, T; Battegay, M; Bernasconi, E; Cavassini, M; Furrer, H; Hirschel, B; Vernazza, P; Francioli, P; Bonhoeffer, S; Ledergerber, B; Günthard, H (2009). Long-term trends of HIV type 1 drug resistance prevalence among antiretroviral treatment-experienced patients in Switzerland. Clinical Infectious Diseases, 48(7):979-987.

Conen, A; Fehr, J; Glass, T R; Furrer, H; Weber, R; Vernazza, P; Hirschel, B; Cavassini, M; Bernasconi, E; Bucher, H C; Battegay, M (2009). Self-reported alcohol consumption and its association with adherence and outcome of antiretroviral therapy in the Swiss HIV Cohort Study. Antiviral Therapy, 14(3):349-357.

Yerly, S; Junier, T; Gayet-Ageron, A; Amari, E B E; von Wyl, V; Günthard, H F; Hirschel, B; Zdobnov, E; Kaiser, L (2009). The impact of transmission clusters on primary drug resistance in newly diagnosed HIV-1 infection. AIDS, 23(11):1415-1423.

Weber, R; Huber, M; Rickenbach, M; Furrer, H; Elzi, L; Hirschel, B; Cavassini, M; Bernasconi, E; Schmid, P; Ledergerber, B (2009). Uptake of and virological response to antiretroviral therapy among HIV-infected former and current injecting drug users and persons in an opiate substitution treatment programme: the Swiss HIV Cohort Study. HIV Medicine, 10(7):407-416.

Young, J; Bucher, H C; Guenthard, H F; Rickenbach, M; Fux, C A; Hirschel, B; Cavassini, M; Vernazza, P; Bernasconi, E; Battegay, M (2009). Virological and immunological responses to efavirenz or boosted lopinavir as first-line therapy for patients with HIV. Antiviral Therapy, 14(6):771-779.

Vo, N T T; Ledergerber, B; Keiser, O; Hirschel, B; Furrer, H; Battegay, M; Cavassini, M; Bernasconi, E; Vernazza, P; Weber, R (2008). Durability and outcome of initial antiretroviral treatments received during 2000-2005 by patients in the Swiss HIV Cohort Study. Journal of Infectious Diseases, 197(12):1685-1694.

Rauch, A; Nolan, D; Furrer, H; McKinnon, E; John, M; Mallal, S; Gaudieri, S; Günthard, H F; Schmid, P; Battegay, M; Hirschel, B; Telenti, A; James, I (2008). HLA-Bw4 homozygosity is associated with an impaired CD4 T cell recovery after initiation of antiretroviral therapy. Clinical Infectious Diseases, 46(12):1921-1925.

El Amari, E B; Toutous-Trellu, L; Gayet-Ageron, A; Baumann, M; Cathomas, G; Steffen, I; Erb, P; Mueller, N J; Furrer, H; Cavassini, M; Vernazza, P; Hirsch, H H; Bernasconi, E; Hirschel, B (2008). Predicting the evolution of Kaposi sarcoma, in the highly active antiretroviral therapy era. AIDS, 22(9):1019-1028.

HIV Cohort Study, Switzerland; von Wyl, V; Yerly, S; Klimkait, T; Böni, J; Bürgisser, P; Battegay, M; Bernasconi, E; Cavassini, M; Furrer, H; Hirschel, B; Vernazza, P L; Rickenbach, M; Ledergerber, B; Guenthard, H F (2008). Factors associated with the emergence of K65R in patients with HIV-1 infection treated with combination antiretroviral therapy containing tenofovir. Clinical Infectious Diseases, 46:1299-1309.

Wunder, D M; Fux, C A; Bersinger, N A; Mueller, N J; Hirschel, B; Cavassini, M; Elzi, L; Schmid, P; Bernasconi, E; Mueller, B; Furrer, H (2008). Androgen and gonadotropin patterns differ in HIV-1-infected men who develop lipoatrophy during antiretroviral therapy: a case-control study. HIV Medicine, 9(6):427-432.

Keiser, O; Gayet-Ageron, A; Rudin, C; Brinkhof, M W G; Gremlich, E; Wunder, D; Drack, G; Hirschel, B; de Tejada, B M (2008). Antiretroviral treatment during pregnancy. AIDS, 22(17):2323-2330.

Khanna, N; Opravil, M; Furrer, H; Cavassini, M; Vernazza, P; Bernasconi, E; Weber, R; Hirschel, B; Battegay, M; Kaufmann, G R (2008). CD4+ T cell count recovery in HIV type 1-infected patients is independent of class of antiretroviral therapy. Clinical Infectious Diseases, 47(8):1093-1101.

Wolbers, M; Bucher, H C; Furrer, H; Rickenbach, M; Cavassini, M; Weber, R; Schmid, P; Bernasconi, E; Hirschel, B; Battegay, M (2008). Delayed diagnosis of HIV infection and late initiation of antiretroviral therapy in the Swiss HIV Cohort Study. HIV Medicine, 9(6):397-405.

Joos, B; Fischer, M; Kuster, H; Pillai, S K; Wong, J K; Böni, J; Hirschel, B; Weber, R; Trkola, A; Günthard, H F (2008). HIV rebounds from latently infected cells, rather than from continuing low-level replication. Proceedings of the National Academy of Sciences of the United States of America (PNAS), 105(43):16725-16730.

Franceschi, S; Maso, L D; Rickenbach, M; Polesel, J; Hirschel, B; Cavassini, M; Bordoni, A; Elzi, L; Ess, S; Jundt, G; Mueller, N; Clifford, G M; Swiss HIV Cohort Study (2008). Kaposi sarcoma incidence in the Swiss HIV Cohort Study before and after highly active antiretroviral therapy. British Journal of Cancer, 99(5):800-804.

Nguyen, A; Calmy, A; Schiffer, V; Bernasconi, E; Battegay, M; Opravil, M; Evison, J M; Tarr, P E; Schmid, P; Perneger, T; Hirschel, B; Swiss HIV Cohort Study (2008). Lipodystrophy and weight changes: data from the Swiss HIV Cohort Study, 2000-2006. HIV Medicine, 9(3):142-150.

Glass, T R; De Geest, S; Hirschel, B; Battegay, M; Furrer, H; Covassini, M; Vernazza, P L; Bernasconi, E; Rickenboch, M; Weber, R; Bucher, H C; Swiss HIV Cohort Study (2008). Self-reported non-adherence to antiretroviral therapy repeatedly assessed by two questions predicts treatment failure in virologically suppressed patients. Antiviral Therapy, 13(1):77-85.

Fux, C; Rauch, A; Simcock, M; Bucher, H; Hirschel, B; Opravil, M; Vernazza, P; Cavassini, M; Bernasconi, E; Elzi, L; Furrer, H; Swiss HIV Cohort Study (2008). Tenofovir Use Is Associated with an Increase in Serum Alkaline Phosphatase in the Swiss HIV Cohort Study. Antiviral Therapy, 13:1077-1082.

von Wyl, V; Yerly, S; Böni, J; Bürgisser, P; Klimkait, T; Battegay, M; Furrer, H; Telenti, A; Hirschel, B; Vernazza, P L; Bernasconi, E; Rickenbach, M; Perrin, L; Ledergerber, B; Günthard, H F; Swiss HIV Cohort Study (2007). Emergence of HIV-1 drug resistance in previously untreated patients initiating combination antiretroviral treatment: a comparison of different regimen types. Archives of Internal Medicine, 167(16):1782-1790.

Schüpbach, J; Günthard, H F; Joos, B; Fischer, M B; Böni, J; Tomasik, Z; Yerly, S; Perrin, L; Battegay, M; Furrer, H; Vernazza, P; Bernasconi, E; Hirschel, B (2005). HIV-1 p24 may persist during long-term highly active antiretroviral therapy, increases little during short treatment breaks, and its rebound after treatment stop correlates with CD4(+) T cell loss. JAIDS Journal of Acquired Immune Deficiency Syndromes, 40(3):250-256.

Joos, B; Trkola, A; Fischer, M; Kuster, H; Rusert, P; Leemann, C; Böni, J; Oxenius, A; Price, D A; Phillips, R E; Wong, J K; Hirschel, B; Weber, R; Günthard, H F (2005). Low human immunodeficiency virus envelope diversity correlates with low in vitro replication capacity and predicts spontaneous control of plasma viremia after treatment interruptions. Journal of Virology, 79(14):9026-9037.

Opravil, M; Pechère, M; Speich, R; Joller-Jemelka, H I; Jenni, R; Russi, E W; Hirschel, B; Lüthy, R (1997). HIV-associated primary pulmonary hypertension. A case control study. Swiss HIV Cohort Study. American Journal of Respiratory and Critical Care Medicine, 155(3):990-995.

This list was generated on Tue Jul 25 03:15:09 2017 CEST.